2021 Our Oncodermatology Study Group is excited to announce the creation of a new Working Group on patient-reported symptom monitoring led by Dr Iris Walraven and Dr Corina van den Hurk.
2021 Our Oncodermatology Study Group is excited to announce the creation of a new Working Group on patient-reported symptom monitoring led by Dr Iris Walraven and Dr Corina van den Hurk.
2020 MASCC announces the Study Group Leadership changes for 2020/2022. For the full roster of study group leaders, visit individual study groups on the MASCC website. Be sure to stay in touch with your Study Groups and get involved in their projects. It's the best way to take full advantage of your MASCC membership and work with like-minded colleagues around the world. Contact Study Group Coordinator Leslie Johnson for more information.
2019 The 2019 Annual Cancer Treatment-Related Adverse Events Symposium will be held on Friday, October 25, 2019 and Saturday, October 26, 2019 at the Rockefeller Research Laboratories, 430 East 67th Street, New York, NY. The course is directed by MASCC member Mario E. Lacouture, MD, who is the Director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center.
2015 MASCC Skin Toxicity Study Group Co-Chair Mario Lacouture has collaborated with Dr. George Dranitsaris of Augmentium Pharma Consulting in Toronto, Ontario, on the development of models for predicting the risks of diarrhea and rash in breast cancer patients being treated with lapatnib and capecitabine.